Disease · MONDO_0005070
Comparisons in its trials27
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 27
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rucaparib Cohort A vs Rucaparib Cohort B: Number of Participants Experiencing Treatment-emergent Adverse Events | 63 of 63 | 20 of 20 | 83 | NCT04171700 | Trial comparisons |
| Rucaparib Cohort A vs Rucaparib Cohort B: deaths from any cause | 23 of 63 | 10 of 20 | 83 | NCT04171700 | Trial comparisons |
| Rucaparib Cohort A vs Rucaparib Cohort B: serious adverse events | 13 of 63 | 5 of 20 | 83 | NCT04171700 | Trial comparisons |
| Rucaparib Cohort A vs Rucaparib Cohort B: Best Overall Response Rate by Investigator | 9 of 61 | 2 of 20 | 81 | NCT04171700 | Trial comparisons |
| Segment I: Continuous Dosing Regimens vs Segment II: Intermittent Dosing Regimens: Objective Response Rate | 7 of 54 | 2 of 19 | 73 | NCT02762981 | Trial comparisons |
| Segment I: Continuous Dosing Regimens vs Segment II: Intermittent Dosing Regimens: Clinical Benefit Rate | 13 of 54 | 6 of 19 | 73 | NCT02762981 | Trial comparisons |
| Phase I vs Phase II: Number of Participants With Adverse Events | 22 of 22 | 19 of 19 | 41 | NCT01100931 | Trial comparisons |
| Phase I vs Phase II: serious adverse events | 10 of 22 | 1 of 19 | 41 | NCT01100931 | Trial comparisons |
| Oxaliplatin/ Gemcitabine vs Radiation: serious adverse events | 2 of 19 | 2 of 15 | 34 | NCT00476086 | Trial comparisons |
| Melanoma Cohort vs Tissue Agnostic Cohort: deaths from any cause | 4 of 8 | 6 of 15 | 23 | NCT04985604 | Trial comparisons |
| Melanoma Cohort vs Tissue Agnostic Cohort: serious adverse events | 2 of 8 | 8 of 15 | 23 | NCT04985604 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities | 1 of 10 | 0 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Laboratory Abnormalities | 0 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Physical Examination Abnormalities | 6 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: deaths from any cause | 6 of 10 | 2 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Clinically Significant Vital Signs Abnormalities | 0 of 10 | 0 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: serious adverse events | 7 of 10 | 1 of 3 | 13 | NCT05093322 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: Number of Patients With Dose-Limiting Toxicities (DLT) | 0 of 8 | 2 of 3 | 11 | NCT05093322 | Trial comparisons |
| Cohort 1 (1.0 mg/m^2) vs Cohort 2 (2.6 mg/m^2): deaths from any cause | 0 of 6 | 1 of 3 | 9 | NCT00293215 | Trial comparisons |
| Cohort 1 (1.0 mg/m^2) vs Cohort 2 (2.6 mg/m^2): serious adverse events | 1 of 6 | 1 of 3 | 9 | NCT00293215 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005070/comparisons